R Schermuly
Overview
Explore the profile of R Schermuly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tello K, Gall H, Richter M, Ghofrani A, Schermuly R
Herz
. 2019 May;
44(6):509-516.
PMID: 31101945
The right ventricle (RV) is the main determinant of prognosis in pulmonary hypertension. Adaptation and maladaptation of the RV are of crucial importance. In the course of disease, RV contractility...
2.
Riemekasten G, Kuebler W, Schermuly R, Seyfarth H, Behr J, Grohe C, et al.
Dtsch Med Wochenschr
. 2014 Dec;
139 Suppl 4:S116-20.
PMID: 25489680
No abstract available.
3.
Schermuly R, Grimminger F
Dtsch Med Wochenschr
. 2008 Oct;
133 Suppl 6:S170-2.
PMID: 18814088
Pulmonary hypertension is a vasculoproliferative disorder which is characterized by vasoconstriction and proliferation of vascular cells within the vessel wall. Mostly addressing the increased vascular tone, prostacyclin and its analogues,...
4.
Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T, et al.
Eur Respir J
. 2007 Aug;
30(5):922-7.
PMID: 17690123
For chronic thromboembolic pulmonary hypertension not amenable to pulmonary endarterectomy, effective medical therapy is desired. In an open-label uncontrolled clinical trial, 104 patients (mean +/- sem age 62 +/- 11...
5.
Olschewski H, Rose F, Grunig E, Ghofrani H, Walmrath D, Schulz R, et al.
J Lab Clin Med
. 2001 Dec;
138(6):367-77.
PMID: 11753283
The identification of several mutations of the bone morphogenetic protein receptor 2 (BMPR2) gene, a member of the transforming growth factor beta receptor family, gives hope for new insights into...
6.
Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, Weissmann N, et al.
J Lab Clin Med
. 2001 Dec;
138(5):287-97.
PMID: 11709653
No abstract available.
7.
Wiedemann R, Ghofrani H, Weissmann N, Schermuly R, Quanz K, Grimminger F, et al.
J Am Coll Cardiol
. 2001 Oct;
38(4):1130-6.
PMID: 11583893
Objectives: The goal of this study was to assess atrial natriuretic peptide (ANP) levels during inhalation of iloprost in severe primary (PPH) and nonprimary pulmonary hypertension (NPPH). Background: The ANP...
8.
[Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis]
Olschewski H, Ghofrani H, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al.
Pneumologie
. 2000 Apr;
54(3):133-42.
PMID: 10783653
Pulmonary hypertension is a life-threatening complication of lung fibrosis. Vasodilator therapy is difficult owing to systemic side effects and pulmonary ventilation-perfusion mismatch. We compared the effects of intravenous prostacyclin and...
9.
Olschewski H, Ghofrani H, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al.
Am J Respir Crit Care Med
. 1999 Aug;
160(2):600-7.
PMID: 10430735
Pulmonary hypertension is a life-threatening complication of lung fibrosis. Vasodilator therapy is difficult owing to systemic side effects and pulmonary ventilation-perfusion mismatch. We compared the effects of intravenous prostacyclin and...
10.
Weissmann N, Voswinckel R, Hardebusch T, Rosseau S, Ghofrani H, Schermuly R, et al.
Am J Physiol
. 1999 Jan;
276(1):L90-5.
PMID: 9887060
Hypoxic pulmonary vasoconstriction (HPV) matches lung perfusion to ventilation, thus optimizing gas exchange. NADPH oxidase-related superoxide anion generation has been suggested as part of the signaling response to hypoxia. Because...